Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortTargeted pill that turned a deadly leukaemia into a manageable condition.Targeted pill for EGFR-mutated lung cancer.
Body systemCancerCancer
Drug classTyrosine kinase inhibitorsTyrosine kinase inhibitors
SupplyPrescription onlyWHO essential medicinePrescription only
Main usesChronic myeloid leukaemia, Philadelphia-positive ALL, Gastrointestinal stromal tumour (GIST)EGFR-mutated non-small cell lung cancer (advanced and after surgery)
How it worksSwitches off the faulty protein that makes leukaemia cells grow.Blocks a faulty growth switch in some lung cancers.
Starts working——
Half-lifeAbout 18 hoursAbout 48 hours
Typical adult doseUsually 400 mg once a day with food.80 mg once a day.
FormsTabletTablet
Common side effectsSwelling around the eyes, Muscle cramps, Nausea, Diarrhoea, RashDiarrhoea, Rash, Dry skin, Nail infections
Serious side effectsFluid retention, Low blood counts, Liver injury, Heart failure (rare)Lung inflammation, QT prolongation, Heart failure
Don't take if——
Alcohol——
PregnancyUsually avoidedEffective contraception needed.Usually avoidedContraception needed.
Breastfeeding——
In use since20012015
Brand namesUnited States: GleevecUnited Kingdom: GlivecIndia: Veenat, ImatibUnited States: TagrissoUnited Kingdom: TagrissoIndia: Tagrisso
Legal status——
ATC codeL01EA01L01EB04

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker